Skip to content

Observations on the Clinical Efficacy of Fuganlin Oral Liquid in the Treatment of Paediatric Pneumonia Convalescence with Qi and Yin Injuries and Unresolved Stagnant Heat

Observations on the Clinical Efficacy of Fuganlin Oral Liquid in the Treatment of Paediatric Pneumonia Convalescence with Qi and Yin Injuries and Unresolved Stagnant Heat

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000244
Enrollment
Unknown
Registered
2025-02-13
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia Convalescence

Interventions

control:Western Basic Symptomatic Therapy
pilot:Western Basic Symptomatic Therapy + Fuganlin Oral Liquid

Sponsors

Beijing University of Chinese Medicine Third Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 12 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosis of pneumonia in accordance with the criteria set out in Western medicine; (2) Diagnosis of qi and yin injuries and unresolved stagnant heat in accordance with the criteria set out in Chinese medicine; (3) Age 5-12 years old no restrictions on gender; (4) The children or their guardians provided informed consent.

Exclusion criteria

Exclusion criteria: (1) Children with acute onset; (2) History of bronchial asthma; (3) Excluding other diseases causing wheezing such as primary ciliary dyskinesia congenital bronchopulmonary dysplasia foreign body aspiration tuberculosis cystic fibrosis etc. and children after umbilical cord blood stem cell transplantation; (4) Combined with serious primary diseases of other systems such as cardiovascular hepatic renal and haematopoietic systems or combined with severe malnutrition gastro-oesophageal reflux primary immunodeficiency diseases psychiatric illnesses and serious diseases that affect their quality of life; (5) Those who are participating in clinical trials of other drugs; (6) Those who are unable to undergo regular follow-up.

Design outcomes

Primary

MeasureTime frame
Cough Symptom Score;

Secondary

MeasureTime frame
Improvement of TCM Syndrome Score;Pulmonary Function Test;Fractional Exhaled Nitric Oxide (FeNO) Detection;PedsQL 4.0;

Countries

China

Contacts

Public ContactCui Xia

Beijing University of Chinese Medicine Third Affiliated Hospital

cuixia68@163.com13810374540

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026